SCHEMBL29856340

SCHEMBL29856340

Cn1c(C(C)(C)C)c(C(=O)c2ccc(O)cc2)c2ccncc21

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ROCK2 O75116 8/20 0.38
ADORA3 P0DMS8 1/20 0.38
ADORA2A P29274 1/20 0.38
MAPT P10636 2/20 0.35
ESR1 P03372 1/20 0.35
ESR2 Q92731 1/20 0.35
LMNA P02545 1/20 0.35
PKM P14618 1/20 0.35
HPGD P15428 1/20 0.35
HTT P42858 1/20 0.35
ELANE P08246 1/20 0.35
KDM5A P29375 1/20 0.34
ATM Q13315 1/20 0.34
SLC22A12 Q96S37 1/20 0.34
CYP19A1 P11511 1/20 0.33
HDAC2 Q92769 1/20 0.33
HDAC6 Q9UBN7 1/20 0.33
EGFR P00533 1/20 0.33
SRC P12931 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29856503 0.84 ADORA3 (0.44) ROCK2ADORA3ADORA2AMAPTESR1
SCHEMBL29856173 0.83 ADORA3 (0.40) ROCK2ADORA3ADORA2AMAPTESR1
SCHEMBL29856267 0.81 SRD5A2 (0.46) ROCK2MAPTHTTCYP19A1EGFR
SCHEMBL29856230 0.80 ROCK2 (0.42) ROCK2ADORA3ADORA2AMAPTESR1
SCHEMBL29856214 0.80 KDM5A (0.40) ROCK2ADORA3ADORA2AMAPTESR1
SCHEMBL29856274 0.78 ROCK2 (0.36) ROCK2ADORA3ADORA2AMAPTESR1
SCHEMBL29856145 0.72 POLB (0.51) MAPTESR1ESR2LMNAPKM
SCHEMBL29856192 0.71 KDM5A (0.50) ROCK2MAPTHTTKDM5ASLC22A12
SCHEMBL29856233 0.70 ERN1 (0.39) ROCK2ADORA3ADORA2AMAPTLMNA
SCHEMBL29856217 0.69 TUBB4A (0.41) MAPTESR1ESR2LMNAPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022169974-A1 INHIBITORS OF URAT1 AND PHARMACEUTICAL USES THEREOF NEXYS THERAPEUTICS, INC. (US) 2022-08-11 WO disclosed